Population-based disparities in survival among patients with core-binding factor acute myeloid leukemia: a SEER
Andrew M Brunner1, Traci M Blonquist2, Hossein Sadrzadeh3
1Massachusetts General Hospital/Harvard Medical School, Boston, MA, United States; Dana Farber Cancer Institute, Boston, MA, United States.
Abstract:
We performed a retrospective population-based study using the SEER database to assess survival trends in CBF-AML between 2000 and 2010. Median OS increased from 16 months in 2000-2002 to 25 months in 2006-2008 (P=0.002). The 3-year OS rate for patients with inv(16) was 57.3%, but in t(8;21) was only 35.5%. Patients aged 75-84 had worse survival than patients aged 15-44 (HR 5.61, P=0.0002). Black race was associated with higher mortality (HR 1.50, P=0.03). Compared to clinical trial outcomes, CBF-AML survival is poorer in the general population, particularly among African Americans and the elderly, and in t(8;21) compared to inv(16) AML.
Related Concept Videos
Cancer Survival Analysis
Bone Marrow Sampling and Transplants
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
Factors Affecting Protein-Drug Binding: Patient-Related Factors
Age stands as a key determinant in protein-drug binding. Neonates, characterized by low albumin content, experience heightened concentrations of unbound drugs such as phenytoin and...
Treatment Resistant Cancers
Treatment Resistent Cancers
Comparing the Survival Analysis of Two or More Groups


